Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Dupixent is a prescription monoclonal antibody containing dupilumab. It is an interleukin-4 receptor alpha antagonist given by subcutaneous injection. Current U.S. indications span several type 2 inflammatory diseases, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, COPD, chronic spontaneous urticaria, bullous pemphigoid, and allergic fungal rhinosinusitis.
read more about dupixent ...Dupilumab binds the interleukin-4 receptor alpha subunit shared by the IL-4 and IL-13 receptor complexes. This blocks IL-4 signaling and IL-13 signaling through the relevant receptor pathways. Reduced signaling in these pathways lowers type 2 inflammatory activity involved in several labeled diseases.
Current labeling includes atopic dermatitis from age 6 months, asthma from age 6, eosinophilic esophagitis from age 1 in patients weighing at least 15 kg, chronic spontaneous urticaria from age 2, and allergic fungal rhinosinusitis from age 6 after sinonasal surgery. Other indications have their own age and disease criteria.
Dosing depends on the condition, age, and body weight. Adults with atopic dermatitis receive a 600 mg starting dose followed by 300 mg every two weeks. Other indications use schedules ranging from every week to every four weeks, with weight-based regimens for several pediatric uses.
Serious concerns include hypersensitivity reactions, conjunctivitis, keratitis, blepharitis, eosinophilic conditions, new-onset psoriasis, joint symptoms, and parasitic infections. Dupixent does not treat acute asthma or COPD symptoms. Live vaccines are avoided immediately before and during therapy.
Dupixent is a monoclonal antibody that blocks IL-4 and IL-13 signaling through IL-4 receptor alpha.
After a 600 mg starting dose, adults receive 300 mg every two weeks.
Yes. Several current indications include pediatric patients, with minimum ages and doses that differ by condition and body weight.
No. Current labeling states that Dupixent is not used for acute asthma symptoms or acute exacerbations.
DailyMed - DUPIXENT (dupilumab) injection, solution. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=595f437d-2729-40bb-9c62-c8ece1f82780. Date Accessed September 29, 2026.
Dupilumab. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548055/. Date Accessed September 29, 2026.
Dupilumab. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Dupilumab. Date Accessed September 29, 2026.
Dupilumab Injection. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a617021.html. Date Accessed September 29, 2026.
DUPIXENT (dupilumab) Full Prescribing Information. https://www.regeneron.com/downloads/dupixent_fpi.pdf?la=en. Date Accessed September 29, 2026.